Q-omics provides the consensus-scored FCGR2B profile across patient tissues and cancer cell-line models. FCGR2B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FCGR2B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, FCGR2B protein abundance shows 38,352 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where FCGR2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCGR2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCGR2B survival associations across molecular data types. FCGR2B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCGR2B RNA expression–survival associations across cancer types. High FCGR2B expression shows unfavorable associations in DLBC and LGG, but favorable associations in HNSC, LUAD, SKCM and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FCGR2B RNA expression.
This table summarizes FCGR2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FCGR2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCGR2B shows lower tumor expression in LIHC, COAD, LUSC and BLCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher FCGR2B RNA expression in tumor versus normal tissue (log2 FC = +1.509, t-test p < 0.001).
This table shows molecular features associated with FCGR2B in patient tissues and cancer cell lines. In patient samples, FCGR2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FCGR2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
